Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Free Cash Flow Chart
Financial Efficiency Indicators
Month
Mar 2012
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Debtor Days
121
101
94
87
88
50
85
99
86
46
134
150
Inventory Days
268
247
249
244
294
329
411
397
396
263
573
216
Days Payable
170
118
106
107
98
122
154
207
179
35
100
93
Cash Conversion Cycle
220
230
237
224
285
258
342
288
303
274
607
273
Working Capital Days
208
161
159
146
169
151
239
161
216
190
653
588
ROCE %
14%
13%
12%
11%
12%
22%
9%
7%
-3%
-1%
-3%
-52%
Financial Efficiency Indicators Chart
Share Holding Pattern
Month
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Promoters
28.57%
28.57%
28.57%
28.57%
21.98%
20.96%
20.96%
20.96%
20.94%
20.94%
20.94%
20.94%
FIIs
3.10%
2.66%
1.85%
1.64%
1.64%
1.64%
1.64%
1.64%
1.64%
1.64%
1.64%
1.64%
Government
0.12%
0.12%
0.12%
0.12%
0.12%
0.12%
0.12%
0.12%
0.12%
0.12%
0.12%
0.12%
Public
68.21%
68.65%
69.47%
69.67%
76.27%
77.29%
77.28%
77.29%
77.30%
77.30%
77.29%
77.30%
No. of Shareholders
37,989
51,963
50,928
52,074
53,110
53,376
52,398
51,026
50,683
49,503
49,038
49,027
Shareholding Pattern Chart
No. of Shareholders
This stock is not held by any mutual fund
ROCE Trend
EPS Trend
Key Financial Ratios
Month
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
FaceValue
2.00
2.00
2.00
2.00
2.00
Basic EPS (Rs.)
-39.62
-8.16
-8.67
-13.16
6.95
Diluted EPS (Rs.)
-39.62
-7.92
-8.42
-12.77
6.67
Cash EPS (Rs.)
-26.55
-5.95
-1.98
-5.09
15.04
Book Value[Excl.RevalReserv]/Share (Rs.)
0.17
39.35
47.47
56.85
70.35
Book Value[Incl.RevalReserv]/Share (Rs.)
4.75
43.93
52.05
61.43
74.96
Revenue From Operations / Share (Rs.)
22.57
28.62
103.90
127.70
159.37
PBDIT / Share (Rs.)
-22.47
-0.81
4.77
1.97
24.25
PBIT / Share (Rs.)
-35.55
-3.02
-1.93
-6.10
16.15
PBT / Share (Rs.)
-39.88
-7.82
-8.43
-13.20
8.00
Net Profit / Share (Rs.)
-39.62
-8.16
-8.67
-13.16
6.95
NP After MI And SOA / Share (Rs.)
-39.62
-8.16
-8.67
-13.16
6.95
PBDIT Margin (%)
-99.59
-2.86
4.58
1.54
15.21
PBIT Margin (%)
-157.53
-10.56
-1.85
-4.77
10.13
PBT Margin (%)
-176.72
-27.32
-8.10
-10.33
5.02
Net Profit Margin (%)
-175.59
-28.50
-8.34
-10.30
4.36
NP After MI And SOA Margin (%)
-175.59
-28.50
-8.34
-10.30
4.36
Return on Networth / Equity (%)
-23087.35
-20.73
-18.26
-23.14
9.88
Return on Capital Employeed (%)
-52.25
-2.80
-1.68
-3.51
9.25
Return On Assets (%)
-33.24
-5.34
-5.57
-4.93
2.46
Long Term Debt / Equity (X)
43.79
0.18
0.14
0.99
0.73
Total Debt / Equity (X)
266.03
1.10
0.64
1.89
1.30
Asset Turnover Ratio (%)
0.16
0.18
0.12
0.16
0.14
Current Ratio (X)
0.78
1.36
1.55
1.27
1.38
Quick Ratio (X)
0.59
0.71
0.80
0.61
0.75
Inventory Turnover Ratio (X)
1.17
0.57
0.24
0.37
0.31
Dividend Payout Ratio (NP) (%)
0.00
0.00
0.00
0.00
574.49
Dividend Payout Ratio (CP) (%)
0.00
0.00
0.00
0.00
265.44
Earning Retention Ratio (%)
0.00
0.00
0.00
0.00
-474.49
Cash Earning Retention Ratio (%)
0.00
0.00
0.00
0.00
-165.44
Interest Coverage Ratio (X)
-5.19
-0.17
0.73
0.27
2.97
Interest Coverage Ratio (Post Tax) (X)
-8.15
-0.70
-0.33
-0.85
1.85
Enterprise Value (Cr.)
430.11
471.51
378.03
898.62
854.91
EV / Net Operating Revenue (X)
2.30
1.99
0.43
0.84
0.65
EV / EBITDA (X)
-2.31
-69.44
9.57
54.91
4.27
MarketCap / Net Operating Revenue (X)
0.29
0.50
0.15
0.05
0.14
Retention Ratios (%)
0.00
0.00
0.00
0.00
-474.49
Price / BV (X)
38.87
0.36
0.33
0.12
0.33
Price / Net Operating Revenue (X)
0.29
0.50
0.15
0.05
0.14
EarningsYield
-5.94
-0.56
-0.54
-1.81
0.29
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Fair Value
Fair Value: 531.20
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
Undervalued: 10,631.33% compared to the current price 4.95
Default values used*: Deafault value of 15 for Stock P/E is used
Intrinsic Value: 276.46
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.
Undervalued: 5,485.04% compared to the current price 4.95
Default values used*: Deafault value of 15 for Stock P/E is used
Last 5 Year EPS CAGR: -47.96%
*Investments are subject to market risks
Strength and Weakness
Strength
Weakness
The stock has a low average ROCE of 3.42%, which may not be favorable.
The stock has a high average Working Capital Days of 253.42, which may not be favorable.
The stock has a high average Cash Conversion Cycle of 295.08, which may not be favorable.
The company has higher borrowings (812.69) compared to reserves (450.85), which may suggest financial risk.
The company has not shown consistent growth in sales (162.15) and profit (-1.31).
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vivimed Labs Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
✗ ROE%: -23087.35% (Industry Average ROE: 15.26%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
✓ Stock P/E: (Industry average Stock P/E: 61.52)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
✗ Total Debt / Equity: 266.03
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:★☆☆☆☆
About the Company
Vivimed Labs Ltd. is a Public Limited Listed company incorporated on 22/09/1988 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L02411KA1988PLC009465 and registration number is 009465. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 218.37 Cr. and Equity Capital is Rs. 16.58 Cr. for the Year ended 31/03/2022.
Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Vivimed Labs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
